Collectively this highlights a potential pitfall in using phosphorylated tau alone as biomarker evidence of Alzheimer’s disease pathology for diagnosis [17], or for clinical trial enrolment, as in the TRAILBAZER-ALZ 3 donanemab trial [4]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.